Endpoints: AveXis wants $400M more for promising SMA gene therapy; ShangPharma partners with Icahn School of Medicine at Mount Sinai
“ShangPharma Innovation, a VC firm that focuses on seed investments, has struck a deal with Icahn School of Medicine at Mount Sinai to fuel research behind early-stage drugs. Under the multi-year collaboration deal, ShangPharma will provide R&D funding at the school’s clinical institutes in New York. Led by CEO Walter Moos, ShangPharma will also provide research services from CRO Shanghai ChemPartner. “This partnership was fueled by the groundbreaking technologies from innovators here at Mount Sinai,” said Erik Lium, senior VP of Mount Sinai Innovation Partners, in a statement. “Our expertise in commercially-relevant translational research, coupled with ShangPharma Innovation’s drug development capabilities will advance much needed medicines to patients worldwide.”
Heidi Chokeir, Ph.D.